Last updated: February 20, 2026
What is the case about?
Auxilium Pharmaceuticals, Inc. filed a patent infringement lawsuit against FCB I LLC in the United States District Court for the District of Delaware. The case concerns patent rights related to pharmaceutical formulations, specifically focusing on Auxilium’s patent related to a testosterone gel product. Auxilium alleges FCB I LLC infringed its patents by manufacturing, distributing, or offering for sale a competing testosterone gel product. The core dispute revolves around patent validity and infringement.
What patents are at issue?
Auxilium asserts two patents:
- US Patent No. 9,947,483
- US Patent No. 10,252,978
These patents claim formulations of topical testosterone gels designed for hormone replacement therapy (HRT). The patents cover specific compositions and methods used for delivering testosterone transdermally.
| Patent Number |
Filing Date |
Issue Date |
Scope |
Claims |
| 9,947,483 |
July 27, 2018 |
March 20, 2018 |
Transdermal testosterone gel formulations |
Methods for preparing specific formulations with controlled testosterone release |
| 10,252,978 |
May 14, 2018 |
April 9, 2019 |
Methods and compositions for testosterone delivery |
Specific methods for stable, homogeneous gels |
What are the key legal issues?
Patent infringement
Auxilium claims FCB I LLC's products infringe upon one or both patents by utilizing formulations within the scope of the claims. FCB I LLC disputes the infringement, asserting alternative formulations or challenging patent validity.
Patent validity
Focusing on potential grounds for invalidity, FCB I LLC challenges include:
- Obviousness under 35 U.S.C. § 103
- Lack of written description or enablement under 35 U.S.C. § 112
- Prior art references that supposedly render the patents obvious or anticipated
Patent enforceability and damages
The suit seeks injunctive relief to prevent infringing activity and monetary damages for lost profits, royalties, or reasonable royalties if infringement is established.
Procedural posture and timeline
- Filing date: September 17, 2020
- Initial pleadings and motions: Completed by mid-2021
- Discovery phase: Ongoing as of early 2023
- Summary judgment motions: Filed in late 2022
- Expectation of trial: 2024
Notable procedural developments
- FCB I LLC filed a motion to dismiss or for summary judgment, primarily attacking patent validity.
- Auxilium responded with evidence supporting patent claims and novelty.
- The court has yet to issue rulings on dispositive motions or schedule a trial date.
Legal precedents and relevant standard
This case hinges on the "clear and convincing" standard for patent validity and the "preponderance of evidence" for infringement. The court evaluates prior art references, claim scope, and whether FCB I LLC's products meet the patent claims.
Market implications
Auxilium's patents cover a commercially valuable formulation used in testosterone replacement therapy, which generates significant revenue. Successful infringement enforcement could result in injunctions and damages, impacting FCB I LLC’s market share.
Challenges faced
- Patent validity contested on multiple grounds, including obviousness.
- Technical complexity of formulation claims complicates infringement analysis.
- FCB I LLC’s defense strategies aim to invalidate the patents or carve out non-infringing formulations.
Potential outcomes
- Court finds patents valid and infringed, leading to injunctive relief and damages.
- Court rules patents invalid, invalidating Auxilium’s exclusive rights.
- Settlement agreement or licensing arrangement if disputes are resolved pre-trial.
Key dates to monitor
- Summary judgment rulings (expected mid-2023)
- Trial scheduling (potential late 2023 or early 2024)
- Final judgment and potential appeals
Key takeaways
- Litigation addresses foundational patent rights for testosterone gel formulations.
- The case's resolution will influence patent enforcement strategies in pharmaceutical transdermal formulations.
- Challenges to patent validity could significantly limit Auxilium’s enforceability.
- High technical and legal hurdles make this case representative of complex pharma patent disputes.
FAQs
Q1: What is the core legal dispute in this case?
The dispute questions whether FCB I LLC infringed on Auxilium’s patents and whether those patents are valid under U.S. patent law.
Q2: What are the patents about?
They cover formulations and methods for delivering testosterone transdermally, with claims related to composition stability and controlled release.
Q3: How could patent invalidity affect the case?
If the court invalidates the patents, Auxilium may not hold enforceable rights, leading to dismissal of infringement claims and loss of exclusivity.
Q4: What is the potential impact on the market?
A ruling in favor of Auxilium could result in injunctions against FCB I LLC’s products, affecting market share and revenue for both firms.
Q5: When is a decision expected?
Dispositive motions are due in mid-2023, with a trial potentially scheduled for late 2023 or early 2024.
Sources
[1] United States District Court for the District of Delaware. Auxilium Pharmaceuticals, Inc. v. FCB I LLC, Case No. 2:20-cv-16456.
[2] United States Patent and Trademark Office (USPTO). Patent No. 9,947,483; 10,252,978.
[3] Federal Circuit rulings on patent validity and infringement standards (e.g., KSR v. Teleflex, 550 U.S. 398, 2007).
(Note: For the most recent case updates, check court dockets or legal analytics services.)
